1. Show article details.

    Stocks That Hit 52-Week Lows On Tuesday

    Benzinga – 12:13 PM ET 05/24/2022

      On Tuesday, 540 companies set new 52-week lows. These stocks set new 52-week lows on Tuesday: Be sure to monitor Benzinga for the news traders need!

  2. Show article details.

    Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

    Benzinga – 8:09 AM ET 05/24/2022

    Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

  3. Show article details.

    Dexcom Announces Upcoming Conference Presentation

    Business Wire – 8:00 AM ET 05/23/2022

    DexCom, Inc. (DXCM) today announced that Brice Bobzien, Senior Vice President, Finance, will present an update on the company at the Piper Sandler Ophthalmology and Diabetes Symposium on Wednesday, May 25, 2022 at 1:00 p.m.. Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.

  4. Show article details.

    Dexcom Announces Upcoming Conference Presentations

    Business Wire – 8:00 AM ET 05/10/2022

    DexCom, Inc. (DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor conferences: Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.

  5. Show article details.

    DexCom Earnings Perspective: Return On Invested Capital

    Benzinga – 9:57 AM ET 05/05/2022

    Pulled from Benzinga Pro data, DexCom posted Q1 earnings of $97.30 million, an increase from Q4 of 601.55%. Sales dropped to $628.80 million, a 9.94% decrease between quarters. Earnings data without context is not clear and can difficult to base trading decisions on. It is important to keep in mind that ROIC evaluates past performance and is not used as a predictive tool.

  6. Show article details.

    If You Invested $1000 In DexCom 10 Years Ago, Here's How Much You Would Have Today

    Benzinga – 7:06 PM ET 05/02/2022

    DexCom has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of $39.95 billion. Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 10 years ago, it would be worth $40,310.89 today based on a price of $407.14 for DXCM at the time of writing.

  7. Show article details.

    Read Here Why Did This Analyst Cut DexCom's Price Target

    Benzinga – 1:56 PM ET 04/29/2022

  8. Show article details.

    Dexcom Updates First Quarter 2022 Conference Call for April 28, 2022 at 5:30 p.m. Eastern Time

    Business Wire – 5:27 PM ET 04/28/2022

    DexCom, Inc. (DXCM) has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. To listen to the conference call, please dial 374-5140 or 400-0571 and use the confirmation number "41691074#" approximately five minutes prior to the start time.

  9. Show article details.

    Recap: DexCom Q1 Earnings

    Benzinga – 5:06 PM ET 04/28/2022

    DexCom reported its Q1 earnings results on Thursday, April 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. DexCom missed estimated earnings by 38.46%, reporting an EPS of $0.32 versus an estimate of $0.52. Revenue was up $123.80 million from the same period last year.

  10. Show article details.

    BRIEF-Dexcom Reports Q1 Non-GAAP EPS $0.32

    Reuters – 4:39 PM ET 04/28/2022

    Dexcom Inc (DXCM): * DEXCOM REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * Q1 NON-GAAP EARNINGS PER SHARE $0.32. * Q1 GAAP EARNINGS PER SHARE $0.93. * SEES FY REVENUE ABOUT $2.82 BILLION TO $2.94 BILLION. * Q1 REVENUE ROSE 25 PERCENT TO $628.8 MILLION. * REITERATING GUIDANCE FOR FISCAL YEAR 2022.

  11. Show article details.

    Dexcom Reports First Quarter 2022 Financial Results

    Business Wire – 4:03 PM ET 04/28/2022

    DexCom, Inc. (DXCM) today reported its financial results as of and for the quarter ended March 31, 2022. First Quarter 2022 Financial Highlights: Strategic Highlights: “Dexcom (DXCM) is off to a great start in 2022, advancing a number of strategic initiatives that strengthen our foundation for long-term growth,” said Kevin Sayer, Dexcom’s chairman, president and CEO.

  12. Show article details.

    Earnings Scheduled For April 28, 2022

    Benzinga – 4:50 AM ET 04/28/2022

      ** PBF Energy is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion. ** Merck & Co is estimated to report quarterly earnings at $1.83 per share on revenue of $14.68 billion. ** Smith & Nephew is estimated to report earnings for its first quarter. ** Domino's Pizza is estimated to report quarterly earnings at $3.05 per share on revenue of $1.03 billion.

  13. Show article details.

    DexCom's Earnings: A Preview

    Benzinga – 3:57 PM ET 04/27/2022

    DexCom is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Analysts estimate that DexCom will report an earnings per share of $0.52. DexCom bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

  14. Show article details.

    Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes

    Benzinga – 1:36 PM ET 04/27/2022

    Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes

  15. Show article details.

    DexCom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More Choice to People With Diabetes

    Business Wire – 2:00 AM ET 04/26/2022

    SAN DIEGO---- DexCom, Inc. (DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global portfolio of real-time continuous glucose monitoring systems at the 15th International Conference on Advanced Technologies and Treatments for Diabetes held April 27-30, 2022 in Barcelona.

  16. Show article details.

    Markets Fall Sharply Amid Ongoing Rate Hike Concerns

    Benzinga – 4:09 PM ET 04/22/2022

    The S&P 500 traded lower for the third week in a row as investors brace for a potential 0.5% interest rate hike by the Federal Reserve. U.S. indices traded sharply lower Friday on continued weakness following comments from Federal Reserve Chair Powell suggesting a rate hike of 50 basis points is possible for May. The Fed has indicated it may move quicker on rate hikes to curb inflation.

  17. Show article details.

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    Benzinga – 5:41 PM ET 04/19/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  18. Show article details.

    Dexcom Publishes Annual Sustainability Report

    Business Wire – 8:45 AM ET 04/07/2022

    DexCom, Inc. (DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today released its third annual Sustainability Report. “At Dexcom (DXCM), we remain focused on how we can better serve our stakeholders, including customers, employees, caregivers, investors, and communities,” said Kevin Sayer, chairman, president and CEO of Dexcom.

  19. Show article details.

    Here's How Much $100 Invested In DexCom 5 Years Ago Would Be Worth Today

    Benzinga – 3:33 PM ET 04/06/2022

    DexCom has outperformed the market over the past 5 years by 32.15% on an annualized basis producing an average annual return of 45.92%. Currently, DexCom has a market capitalization of $49.71 billion. Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 5 years ago, it would be worth $652.97 today based on a price of $510.43 for DXCM at the time of writing.

  20. Show article details.

    Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

    Business Wire – 3:29 AM ET 04/01/2022

    On the heels of the latest NICE guidelines, Dexcom ONE is in review by NHS England for addition to the Drug Tariff DexCom, Inc. (DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the new Dexcom ONE Continuous Glucose Monitoring System will launch in the United Kingdom this May. The Dexcom ONE system is an easy-to-use real-time CGM that will b...

Page:

Today's and Upcoming Events

  • Jul
    27

    DXCM to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • Apr
    28

    DXCM announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.